Web Analytics Made Easy - StatCounter
Category

Multiple Sclerosis

The influence of THC:CBD oromucosal spray on driving ability in patients with multiple sclerosis-related spasticity.

By | Driving, Immune System Diseases , Multiple Sclerosis, Muscle Spasticity, Muscular Diseases

Authors: Elisabeth G. Celius, Carlos Vila
Brain and Behavior, 6 April 2018

BACKGROUND: Driving ability is a key function for the majority of patients with multiple sclerosis (MS) to help maintain daily interactions. Both physical and cognitive disability, as well as treatments, may affect the ability to drive. Spasticity is a common symptom associate…

Read More

Oral administration of cannabis with lipids leads to high levels of cannabinoids in the intestinal lymphatic system and prominent immunomodulation.

By | Immune System Diseases , Multiple Sclerosis

Authors: Atheer Zgair, Jong Bong Lee, Jonathan C. M. Wong, Dhiaa A. Taha, Jehan Aram, et al
Scientific Reports, 6 November 2017

Cannabidiol (CBD) and ∆9-tetrahydrocannabinol (THC) have well documented immunomodulatory effects in vitro, but not following oral administration in humans. Here we show that oral co-administration of cannabinoids with lipids can substantially increase their intestinal lympha…

Read More

Randomized controlled trial of Sativex to treat detrusor overactivity in multiple sclerosis.

By | Immune System Diseases , Multiple Sclerosis

Authors: R. B. C. Kavia, D. De Ridder, C. S. Constantinescu, C. G. Stott, C. J. Fowler
Multiple Sclerosis Journal, November 2016

BACKGROUND: Bladder dysfunction is a common feature of multiple sclerosis (MS). OBJECTIVE: In this study we aimed to assess the efficacy, tolerability and safety of Sativex(®) (nabiximols) as an add-on therapy in alleviating bladder symptoms in patients with MS. METHODS: We un…

Read More

Clinical Endocannabinoid Deficiency Reconsidered: Current Research Supports the Theory in Migraine, Fibromyalgia, Irritable Bowel, and Other Treatment-Resistant Syndromes.

By | Anorexia, Behavioral Health, Brain Disorders, Clinical Endocannabinoid Deficiency, Digestive System Diseases, Headache Disorders, Immune System Diseases , Irritable Bowel Syndrome, Multiple Sclerosis, Nervous System Diseases, Parkinsonian Disorders, Stress Disorders - Post-Traumatic

Authors: Ethan B. Russo
Cannabis and Cannabinoid Research, 1 July 2016

Medicine continues to struggle in its approaches to numerous common subjective pain syndromes that lack objective signs and remain treatment resistant. Foremost among these are migraine, fibromyalgia, and irritable bowel syndrome, disorders that may overlap in their affected p…

Read More

Medical Marijuana for Treatment of Chronic Pain and Other Medical and Psychiatric Problems: A Clinical Review.

By | Immune System Diseases , Medical Cannabis, Multiple Sclerosis, Muscle Spasticity, Muscular Diseases, Nervous System Diseases, Neuromuscular Diseases, Pain

Authors: Kevin P. Hill
JAMA, 23 June 2015

IMPORTANCE: As of March 2015, 23 states and the District of Columbia had medical marijuana laws in place. Physicians should know both the scientific rationale and the practical implications for medical marijuana laws. OBJECTIVE: To review the pharmacology, indications, and law…

Read More

Role of Endocannabinoid Activation of Peripheral CB1 Receptors in the Regulation of Autoimmune Disease.

By | Arthritis, Immune System Diseases , Joint Diseases (Arthrosis), Multiple Sclerosis

Authors: Jessica Margaret Sido, Prakash S. Nagarkatti, Mitzi Nagarkatti
International Reviews of Immunology, 2015

The impact of the endogenous cannabinoids (AEA, 2-AG, PEA, and virodamine) on the immune cell expressed cannabinoid receptors (CB1, CB2, TRPV-1, and GPR55) and consequent regulation of immune function is an exciting area of research with potential implications in the preventio…

Read More

Multiple sclerosis and extract of cannabis: results of the MUSEC trial.

By | Immune System Diseases , Multiple Sclerosis, Pain

Authors: John Peter Zajicek, Jeremy C. Hobart, Anita Slade, David Barnes, Paul G. Mattison
Journal of Neurology, Neurosurgery, & Psychiatry, November 2012

OBJECTIVE: Multiple sclerosis (MS) is associated with chronic symptoms, including muscle stiffness, spasms, pain and insomnia. Here we report the results of the Multiple Sclerosis and Extract of Cannabis (MUSEC) study that aimed to substantiate the patient based findings of pr…

Read More

Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial.

By | Immune System Diseases , Multiple Sclerosis, Muscle Spasticity, Muscular Diseases, Pain

Authors: Jody Corey-Bloom, Tanya Wolfson, Anthony Gamst, Shelia Jin, Thomas D. Marcotte, et al
CMAJ, 10 July 2012

BACKGROUND: Spasticity is a common and poorly controlled symptom of multiple sclerosis. Our objective was to determine the short-term effect of smoked cannabis on this symptom. METHODS: We conducted a placebo-controlled, crossover trial involving adult patients with multiple s…

Read More

An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis.

By | Immune System Diseases , Multiple Sclerosis

Authors: C. M. Brady, R. DasGupta, C. Dalton, O. J. Wiseman, K. J. Berkley, C. J. Fowler
Multiple Sclerosis Journal, 1 August 2004

The majority of patients with multiple sclerosis (MS) develop troublesome lower urinary tract symptoms (LUTS). Anecdotal reports suggest that cannabis may alleviate LUTS, and cannabinoid receptors in the bladder and nervous system are potential pharmacological targets. In an o…

Read More